OTCMKTS:NVZMY - NOVOZYMES A/S/S Stock Price, Forecast & News

NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY."

NOVOZYMES A/S/S declared an annual dividend on Friday, January 24th. Shareholders of record on Friday, February 28th will be given a dividend of $0.517 per share on Tuesday, March 17th. This represents a yield of 1.01%. The ex-dividend date is Thursday, February 27th. This is an increase from NOVOZYMES A/S/S's previous annual dividend of $0.50. View NOVOZYMES A/S/S's Dividend History.

NOVOZYMES A/S/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for NOVOZYMES A/S/S.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NOVOZYMES A/S/S.

News articles about NVZMY stock have been trending very negative on Monday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NOVOZYMES A/S/S earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for NOVOZYMES A/S/S.

Some companies that are related to NOVOZYMES A/S/S include Biogen (BIIB), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), argenx (ARGX), Moderna (MRNA), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT) and Ablynx (ABLYF).

Based on aggregate information from My MarketBeat watchlists, some companies that other NOVOZYMES A/S/S investors own include ManpowerGroup (MAN), TeamHealth (TMH), Novo Nordisk A/S (NVO), FOX (FOXA), Level One Bancorp (LEVL), Duke Energy (DUK), Emerson Electric (EMR), AT&T (T), Zayo Group (ZAYO) and DANSKE BK A/S/S (DNKEY).

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVZMY stock can currently be purchased for approximately $54.35.

NOVOZYMES A/S/S has a market capitalization of $16.14 billion and generates $2.28 billion in revenue each year. The biotechnology company earns $511 million in net income (profit) each year or $1.75 on an earnings per share basis. NOVOZYMES A/S/S employs 6,427 workers across the globe.View Additional Information About NOVOZYMES A/S/S.

The official website for NOVOZYMES A/S/S is http://www.novozymes.com/.

NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]